Patients (n) | 23 | 5 (22%) | 18 (78%) |
Age (y) | | | |
Mean ± SD | 51 ± 12.7 | 50.6 ± 9.9 | 52.2 ± 13.3 |
Range | 34−78 | 37–60 | 34–78 |
Histology | | | |
Invasive ductal carcinoma | 22 (95%) | 4 (80%) | 18 (100%) |
Metaplastic carcinoma | 1 (5%) | 1 (20%) | |
Elston–Ellis grade | | | |
I | 2 (9%) | | 2 (11%) |
II | 7 (30%) | | 7 (39%) |
III | 14 (61%) | 5 (100%) | 9 (50%) |
HR status | | | |
Positive | 11 (43%) | 1 (20%) | 10 (55%) |
Negative | 12 (57%) | 4 (80%) | 8 (45%) |
HER2 receptor status | | | |
Positive | 5 (22%) | 2 (40%) | 3 (17%) |
Negative | 18 (78%) | 3 (60%) | 15 (83%) |
Triple-negative cancer | 7 (30%) | 2 (40%) | 5 (28%) |
Ki-67 | | | |
<25% | 7 (30%) | 1 (20%) | 6 (33%) |
≥25% | 14 (61%) | 4 (80%) | 10 (55%) |
Unknown | 2 (9%) | | 2 (12%) |
NACT | | | |
Anthracycline alone | 14 (61%) | 4 (80%) | 10 (55%) |
Anthracycline and docetaxel | 9 (39%) | 1 (20%) | 8 (45%) |
Clinical response | | | |
Complete response | 5 (22%) | 3 (60%) | 2 (11%) |
Partial response | 15 (65%) | 2 (40%) | 13 (72%) |
Stable disease | 3 (13%) | | 3 (17%) |
Survival parameters (mo) | | | |
DMFS (distant metastasis-free survival) | 52.6 | 46 | 54 |
Overall survival | 73.9 | 79.5 | 72.4 |